JP2022526842A - 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法 - Google Patents

脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法 Download PDF

Info

Publication number
JP2022526842A
JP2022526842A JP2021559986A JP2021559986A JP2022526842A JP 2022526842 A JP2022526842 A JP 2022526842A JP 2021559986 A JP2021559986 A JP 2021559986A JP 2021559986 A JP2021559986 A JP 2021559986A JP 2022526842 A JP2022526842 A JP 2022526842A
Authority
JP
Japan
Prior art keywords
insulin
biotin
administered
subject
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526842A5 (https=
JPWO2020210697A5 (https=
Inventor
ダブリュ． ブレア ゲオ
Original Assignee
エスディージー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスディージー インコーポレイテッド filed Critical エスディージー インコーポレイテッド
Publication of JP2022526842A publication Critical patent/JP2022526842A/ja
Publication of JP2022526842A5 publication Critical patent/JP2022526842A5/ja
Publication of JPWO2020210697A5 publication Critical patent/JPWO2020210697A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021559986A 2019-04-12 2020-04-10 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法 Pending JP2022526842A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962833228P 2019-04-12 2019-04-12
US62/833,228 2019-04-12
US202062988748P 2020-03-12 2020-03-12
US62/988,748 2020-03-12
PCT/US2020/027762 WO2020210697A1 (en) 2019-04-12 2020-04-10 Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Publications (3)

Publication Number Publication Date
JP2022526842A true JP2022526842A (ja) 2022-05-26
JP2022526842A5 JP2022526842A5 (https=) 2023-04-17
JPWO2020210697A5 JPWO2020210697A5 (https=) 2023-04-17

Family

ID=72748579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559986A Pending JP2022526842A (ja) 2019-04-12 2020-04-10 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法

Country Status (7)

Country Link
US (3) US10918700B2 (https=)
EP (1) EP3952904A4 (https=)
JP (1) JP2022526842A (https=)
AU (1) AU2020271901A1 (https=)
CA (1) CA3136665A1 (https=)
WO (1) WO2020210697A1 (https=)
ZA (1) ZA202108217B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
WO2018169954A1 (en) * 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006540A1 (en) * 1988-01-13 1989-07-27 Technology Unlimited, Inc. Diabetic control by combined insulin forms
JP2002515417A (ja) * 1998-05-19 2002-05-28 エスディジー、インコーポレイテッド 標的指向リポソーム薬剤送達システム
JP2009507761A (ja) * 2005-05-23 2009-02-26 エスデイージー・インコーポレーテツド インスリンを哺乳動物に送達するための脂質構築物
WO2018169954A1 (en) * 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
JP2020537138A (ja) * 2017-11-09 2020-12-17 ヴィオニア スウェーデン エービー 車両レーダシステムを用いた駐車列の検出

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
CA2389236A1 (en) 1999-11-02 2001-05-10 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
EP1448252B1 (de) * 2001-11-16 2007-04-18 Medinnovation AG Medizinische pumpvorrichtung
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US8211430B2 (en) * 2005-03-04 2012-07-03 Curedm Group Holdings, Llc Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
WO2010080976A1 (en) * 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
KR20200106912A (ko) 2018-01-05 2020-09-15 에스디지,인코포레이티드 당뇨병을 치료하기 위한 지질 기반 나노입자를 포함하는 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006540A1 (en) * 1988-01-13 1989-07-27 Technology Unlimited, Inc. Diabetic control by combined insulin forms
JP2002515417A (ja) * 1998-05-19 2002-05-28 エスディジー、インコーポレイテッド 標的指向リポソーム薬剤送達システム
JP2009507761A (ja) * 2005-05-23 2009-02-26 エスデイージー・インコーポレーテツド インスリンを哺乳動物に送達するための脂質構築物
WO2018169954A1 (en) * 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
JP2020537138A (ja) * 2017-11-09 2020-12-17 ヴィオニア スウェーデン エービー 車両レーダシステムを用いた駐車列の検出

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
'STUDY OF HDV INSULIN VERSUS INSULIN IN TYPE 1 DIABETES SUBJECTS(ISLE-1)(ISLE-1)',［ONLINE］, JPN6024011479, 2018, ISSN: 0005441353 *

Also Published As

Publication number Publication date
US20240139288A1 (en) 2024-05-02
CA3136665A1 (en) 2020-10-15
US20210379160A1 (en) 2021-12-09
EP3952904A4 (en) 2022-12-28
ZA202108217B (en) 2023-12-20
US20200323961A1 (en) 2020-10-15
AU2020271901A1 (en) 2021-11-04
EP3952904A1 (en) 2022-02-16
WO2020210697A1 (en) 2020-10-15
US10918700B2 (en) 2021-02-16

Similar Documents

Publication Publication Date Title
JP7656353B2 (ja) 向上した安定性を有する脂質ベースのナノ粒子
JP2023166021A (ja) インスリン分泌促進性ペプチドの懸濁製剤及び使用
EP3323423B1 (en) Rapid establishment and/or termination of substantial steady-state drug delivery
US20240108585A1 (en) Compositions comprising lipid-based nanoparticles for treating diabetes mellitus
JP2011006428A (ja) インスリン組成物および組成物の製造方法
US20240139288A1 (en) Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
US11077173B2 (en) Lipid-based nanoparticles and methods using same
JP7752343B2 (ja) 経口ペプチド投与
HK40015408A (en) Lipid-based nanoparticles with enhanced stability

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230407

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230531

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241021